Takeo Mukai

Dr. Takeo Mukai

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2018 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
ETEmi Tanaka
Emi Tanaka
YOYuko Ogawa
Yuko Ogawa
TMTakeo Mukai
Takeo Mukai
YSYoshiaki Sato
Yoshiaki Sato
THTakashi Hamazaki
Takashi Hamazaki
MTMasahiro Tsui
Masahiro Tsui
Neonatal brain injury induced by stroke causes significant disability, including cerebral palsy, and there is no effective therapy for stroke. Recently, mesenchymal stem cells (MSCs) have emerged as a promising tool for stem cell-based therapies. In this study, we examined the safety and efficacy of intravenously administered human umbilical cord-derived MSCs (UC-MSCs) in neonatal stroke mice. Pups underwent permanent middle cerebral artery occlusion at postnatal day 12 (P12), and low-dose (1 × 104) or high-dose (1 × 105) UC-MSCs were administered intravenously 48 h after the insult (P14). To evaluate the effect of the UC-MSC treatment, neurological behavior and cerebral blood flow were measured, and neuroanatomical analysis was performed at P28. To investigate the mechanisms of intravenously injected UC-MSCs, systemic blood flowmetry, in vivo imaging and human brain-derived neurotrophic factor (BDNF) measurements were performed. Functional disability was significantly improved in the high-dose UC-MSC group when compared with the vehicle group, but cerebral blood flow and cerebral hemispheric volume were not restored by UC-MSC therapy. The level of exogenous human BDNF was elevated only in the cerebrospinal fluid of one pup 24 h after UC-MSC injection, and in vivo imaging revealed that most UC-MSCs were trapped in the lungs and disappeared in a week without migration toward the brain or other organs. We found that systemic blood flow was stable over the 10 min after cell administration and that there were no differences in mortality among the groups. Immunohistopathological assessment showed that the percent area of Iba1-positive staining in the peri-infarct cortex was significantly reduced with the high-dose UC-MSC treatment compared with the vehicle treatment. These results suggest that intravenous administration of UC-MSCs is safe for a mouse model of neonatal stroke and improves dysfunction after middle cerebral artery occlusion by modulating the microglial reaction in the peri-infarct cortex.

1 July 2017 in Neuroscience
Verified
Journal Article
Closed access
TMTakeo Mukai
Takeo Mukai
YMYuka Mori
Yuka Mori
TSTakahisa Shimazu
Takahisa Shimazu
ATAtsuko Takahashi
Atsuko Takahashi
HTHajime Tsunoda
Hajime Tsunoda
TNTokiko Nagamura-Inoue
Tokiko Nagamura-Inoue

11 April 2020 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
STShunichiro Tsuji
Shunichiro Tsuji
EMElena Di Martino
Elena Di Martino
TMTakeo Mukai
Takeo Mukai
STShoko Tsuji
Shoko Tsuji
TMTakashi Murakami
Takashi Murakami
UÅUlrika Åden
Ulrika Åden
Background: Neuroinflammation plays an important role in neonatal hypoxic-ischemic encephalopathy (HIE). Although microglia are largely responsible for injury-induced inflammatory response, they play beneficial roles in both normal and disease states. However, the effects of microglial depletion on neonatal HIE remain unclear.Methods: Tamoxifen was administered to Cx3cr1CreER/+Rosa26DTA/+(microglia-depleted model) and Cx3cr1CreER/+Rosa26DTA/−(control) mice at P8 and P9 to assess the effect of microglial depletion. The density of microglia was quantified using Iba-1 staining. Moreover, the proportion of resident microglia after the HI insult was analyzed using flow cytometric analysis. At P10, the HI insult was conducted using the Rice-Vannucci procedure at P10. The infarct size and apoptotic cells were analyzed at P13. Cytokine analyses were performed using quantitative polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA) at P13.Results: At P10, tamoxifen administration induced > 99% microglial depletion in DTA+mice. Following HI insult, there was persisted microglial depletion over 97% at P13. Compared to male DTA−mice, male DTA+mice exhibited significantly larger infarct volumes; however, there were no significant differences among females. Moreover, compared to male DTA−mice, male DTA+mice had a significantly higher density of TUNEL+cells in the caudoputamen, cerebral cortex, and thalamus. Moreover, compared to female DTA−mice, female DTA+mice showed a significantly greater number of TUNEL+cells in the hippocampus and thalamus. Compared to DTA−mice, ELISA revealed significantly lower IL-10 and TGF-β levels in both male and female DTA+mice under both normal conditions and after HI (more pronounced).Conclusion: We established a microglial depletion model that aggravated neuronal damage and apoptosis after the HI insult, which was predominantly observed in males.

1 December 2018 in Regenerative Therapy
Verified
Journal Article
Open access
TMTakeo Mukai
Takeo Mukai
ATArinobu Tojo
Arinobu Tojo
TNTokiko Nagamura-Inoue
Tokiko Nagamura-Inoue
Several studies have reported that mesenchymal stromal/stem cells (MSCs) restore neurological damage through their secretion of paracrine factors or their differentiation to neuronal cells. Based on these studies, many clinical trials have been conducted using MSCs for neurological disorders, and their safety and efficacy have been reported. In this review, we provide a brief introduction to MSCs, especially umbilical cord derived-MSCs (UC-MSCs), in terms of characteristics, isolation, and cryopreservation, and discuss the recent progress in regenerative therapies using MSCs for various neurological disorders.

23 January 2020 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
EMElena Di Martino
Elena Di Martino
EBErica Bocchetta
Erica Bocchetta
STShunichiro Tsuji
Shunichiro Tsuji
TMTakeo Mukai
Takeo Mukai
RHRobert A. Harris
Robert A. Harris
UÅUlrika Ådén
Ulrika Ådén
Hypoxic-ischemic (HI) brain injury remains an important cause of brain damage in neonates with potential life-long consequences. Caffeine, which is a competitive inhibitor of adenosine receptors, is commonly used as treatment for preterm apnoea in clinical settings. In the current study, we investigated the effects of caffeine given at 0 h, 6 h, 12 h or 24 h after HI in P10 mouse pups. Open field and rotarod behavioural tests were performed 2 weeks after injury, and brain morphology was then evaluated. Gene expression and immunohistological analyses were assessed in mice 1- and 5-day post-HI. A single dose of caffeine directly after HI resulted in a reduction of the lesion in the grey and white matter, judged by immunostaining of MAP2 and MBP, respectively, compared to PBS-treated controls. In addition, the number of amoeboid microglia and apoptotic cells, the area covered by astrogliosis, and the expression of pro-inflammatory cytokines were significantly decreased. Behavioural assessment after 2 weeks showed increased open-field activity after HI, and this was normalised if caffeine was administered immediately after the injury. Later administrations of caffeine did not change the outcomes when compared to the vehicle group. In conclusion, caffeine only yielded neuroprotection and immunomodulation in a neonatal model of brain hypoxia ischaemia if administered immediately after injury.

1 February 2016 in Cytotherapy
Verified
Journal Article
Closed access
TMTakeo Mukai
Takeo Mukai
TNTokiko Nagamura-Inoue
Tokiko Nagamura-Inoue
TSTakahisa Shimazu
Takahisa Shimazu
YMYuka Mori
Yuka Mori
ATAtsuko Takahashi
Atsuko Takahashi
ATArinobu Tojo
Arinobu Tojo